首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2018年 2期丙型肝炎的治疗 => 综述 =>靶向药物治疗肝细胞癌的最新进展
靶向药物治疗肝细胞癌的最新进展
Recent advances in targeted drug therapy for hepatocellular carcinoma
文章发布日期:2018年02月07日  来源:  作者:樊永强, 董胜利  点击次数:1116次  下载次数:257次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:靶向药物对于肝细胞癌的治疗效果在临床上已经被广泛证实。随着科学技术的发展,越来越多的靶向药物相继出现。近期,瑞格菲尼、ramucirumab等靶向药物在相应的临床实验中也表现出了相当的潜力。更多的二线候选药物,比如c-Met抑制剂tivantinib 与cabozantinib、VEGFR-2抑制剂ramuciruma临床试验正在进行。总结了近几年靶向药物治疗肝细胞癌的试验数据及最新进展,为下一步临床试验及治疗提供参考意见。
【Abstract】:More and more clinical trials have proved the efficacy of targeted drugs in the treatment of hepatocellular carcinoma (HCC). With the development of science and technology, more and more targeted drugs have appeared. In recent years, targeted drugs such as regorafenib and ramucirumab have shown great potential in related clinical trials. In addition, there are ongoing clinical trials for second-line candidate drugs, such as c-Met inhibitors tivantinib and cabozantinib and a VEGFR-2 inhibitor ramucirumab. This article summarizes the advances in targeted drug therapy for HCC and related trial data, which provides a reference for further clinical trials and treatment.
【关键字】:癌, 肝细胞; 靶向药物; 药物疗法; 临床试验; 综述
【Key words】:carcinoma, hepatocellular; targeted drug; drug therapy; clinical trial; review
【引证本文】:FAN YQ, DONG SL. Recent advances in targeted drug therapy for hepatocellular carcinoma[J]. J Clin Hepatol, 2018, 34(2): 424-428. (in Chinese)
樊永强, 董胜利. 靶向药物治疗肝细胞癌的最新进展[J]. 临床肝胆病杂志, 2018, 34(2): 424-428.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号